MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 15.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 242,702 shares of the biotechnology company's stock after purchasing an additional 33,238 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.19% of Arrowhead Pharmaceuticals worth $4,562,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Integral Health Asset Management LLC bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $5,170,000. Farallon Capital Management LLC bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $11,821,000. Deutsche Bank AG boosted its position in Arrowhead Pharmaceuticals by 17.0% during the fourth quarter. Deutsche Bank AG now owns 258,964 shares of the biotechnology company's stock worth $4,869,000 after purchasing an additional 37,686 shares during the period. Brevan Howard Capital Management LP boosted its position in Arrowhead Pharmaceuticals by 232.2% during the fourth quarter. Brevan Howard Capital Management LP now owns 34,556 shares of the biotechnology company's stock worth $650,000 after purchasing an additional 24,153 shares during the period. Finally, Captrust Financial Advisors boosted its position in shares of Arrowhead Pharmaceuticals by 13.5% in the fourth quarter. Captrust Financial Advisors now owns 17,074 shares of the biotechnology company's stock valued at $321,000 after acquiring an additional 2,035 shares during the period. Institutional investors own 62.61% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ARWR shares. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Royal Bank of Canada restated an "outperform" rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday. Finally, Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $42.13.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the transaction, the chief executive officer now directly owns 3,773,802 shares of the company's stock, valued at approximately $64,230,110.04. This trade represents a 3.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 275,880 shares of company stock valued at $4,034,037 over the last three months. 4.30% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Price Performance

ARWR traded down $0.26 on Friday, reaching $15.13. The company had a trading volume of 1,230,383 shares, compared to its average volume of 1,505,636. The business has a 50 day simple moving average of $13.32 and a 200 day simple moving average of $17.63. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -2.93 and a beta of 0.89. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same period in the prior year, the business earned ($1.02) earnings per share. As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.